Expert Interview
Discussing the use of Adaptive Biotechnologies’ clonoSEQ assay for minimal residual disease (MRD) testing in patients with multiple myeloma, acute lymphoblastic leukemia (ALL), and chronic lymphocytic leukemia (CLL)
Ticker(s): ADPTInstitution: Humanitas Research Hospital
- Oncologist at Humanitas Research Hospital
- Performs MRD testing for 20 patients per year across multiple myeloma and lymphoid malignancies (ALL/CLL), mainly in selected clinical and research-driven contexts.
- Research interest in gastrointestinal malignancies - particularly colorectal, gastric, and gastroesophageal cancers with emphasis on real-world outcomes, mismatch repair deficiency and Lynch syndrome, treatment sequencing, neoadjuvant strategies, and optimizing therapies for older cancer patients,
In which patient populations (multiple myeloma, ALL, CLL) are you currently using MRD testing, and at what points in the treatment course do you find it most clinically informative?
Added By: sara_adminHow do you incorporate clonoSEQ MRD results into treatment decisions (e.g., therapy escalation or de-escalation, transplant decisions, maintenance strategies, or monitoring frequency)?
Added By: sara_adminWhat advantages or limitations do you see with next-generation sequencing–based MRD testing compared with other MRD assessment methods such as flow cytometry or imaging?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
